Insider · CIK 0002081169
Daniel Joseph Apel
Files at ARWR (ARROWHEAD PHARMACEUTICALS, INC.). First filing Apr 24, 2026, latest Apr 24, 2026.
In brief
Daniel Joseph Apel files SEC Form 4 as CFO at ARWR (ARROWHEAD PHARMACEUTICALS, INC.). Since Apr 24, 2026, Daniel Joseph Apel has reported 0 open-market buys worth $0 and 1 open-market sell worth $934k, the latest filed on Apr 24, 2026.
A track record needs three past buys with six months of prices behind them; Daniel Joseph Apel has 0, so none is measured yet.
The newest scored trade: sold $934k of ARWR on Apr 22, 2026, filed Apr 24, 2026, scored 34 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $934k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ARWR: ARROWHEAD PHARMACEUTICALS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 34Weak | ARROWHEAD PHARMACEUTICALS, INC. | $934k 13,095 shares | -7% | +498% from low0% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Apr 22, 2026 | ARWR Arrowhead Pharmaceuticals Inc. | 13,095 0.01% of outstanding | $934k | Apr 22, 2026 | none |
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -3,208 | $70.11 | $225k | 172,792 | Apr 24, 2026 |
| Apr 22, 2026 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -1,157 | $70.45 | $82k | 171,635 | Apr 24, 2026 |
| Apr 22, 2026 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -8,730 | $71.92 | $628k | 162,905 | Apr 24, 2026 |
| Jan 6, 2026 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | AGrant or award Common Stock | +75,000 | $0.00 | $0 | 176,200 | Jan 8, 2026 |
Questions about Daniel Joseph Apel
Answered from the filings on this page, as of the latest one.
Is Daniel Joseph Apel buying or selling?
In the last 12 months Daniel Joseph Apel reported 0 open-market buys worth $0 and 1 open-market sell worth $934k on SEC Form 4; the latest was sold $934k of ARWR on Apr 22, 2026. Grants, option exercises and tax withholding are not counted.
How did Daniel Joseph Apel's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Daniel Joseph Apel has 0.
Where does Daniel Joseph Apel file Form 4?
Daniel Joseph Apel has filed Form 4 at ARWR (ARROWHEAD PHARMACEUTICALS, INC.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.